These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31015160)

  • 1. Individualized accelerated isotoxic concurrent chemo-radiotherapy for stage III non-small cell lung cancer: 5-Year results of a prospective study.
    De Ruysscher D; van Baardwijk A; Wanders R; Hendriks LE; Reymen B; van Empt W; Öllers MC; Bootsma G; Pitz C; van Eijsden L; Dingemans AC
    Radiother Oncol; 2019 Jun; 135():141-146. PubMed ID: 31015160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term survival of stage T4N0-1 and single station IIIA-N2 NSCLC patients treated with definitive chemo-radiotherapy using individualised isotoxic accelerated radiotherapy (INDAR).
    Reymen B; van Baardwijk A; Wanders R; Borger J; Dingemans AM; Bootsma G; Pitz C; Lunde R; Geraedts W; Lambin P; De Ruysscher D
    Radiother Oncol; 2014 Mar; 110(3):482-7. PubMed ID: 24444527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mature results of a phase II trial on individualised accelerated radiotherapy based on normal tissue constraints in concurrent chemo-radiation for stage III non-small cell lung cancer.
    van Baardwijk A; Reymen B; Wanders S; Borger J; Ollers M; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Lunde R; Peters F; Lambin P; De Ruysscher D
    Eur J Cancer; 2012 Oct; 48(15):2339-46. PubMed ID: 22608261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status.
    Maguire J; Khan I; McMenemin R; O'Rourke N; McNee S; Kelly V; Peedell C; Snee M
    Eur J Cancer; 2014 Nov; 50(17):2939-49. PubMed ID: 25304298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is selective nodal irradiation in non-small cell lung cancer still safe when using IMRT? Results of a prospective cohort study.
    Martinussen HM; Reymen B; Wanders R; Troost EG; Dingemans AC; Öllers M; Houben R; De Ruysscher D; Lambin P; van Baardwijk A
    Radiother Oncol; 2016 Nov; 121(2):322-327. PubMed ID: 27884510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
    Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
    Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall survival and toxicities regarding thoracic three-dimensional radiotherapy with concurrent chemotherapy for stage IV non-small cell lung cancer: results of a prospective single-center study.
    Su SF; Hu YX; Ouyang WW; Lu B; Ma Z; Li QS; Li HQ; Geng YC
    BMC Cancer; 2013 Oct; 13():474. PubMed ID: 24118842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accelerated, Dose escalated, Sequential Chemoradiotherapy in Non-small-cell lung cancer (ADSCaN): a protocol for a randomised phase II study.
    Hatton MQF; Lawless CA; Faivre-Finn C; Landau D; Lester JF; Fenwick J; Simões R; McCartney E; Boyd KA; Haswell T; Shaw A; Paul J
    BMJ Open; 2019 Jan; 9(1):e019903. PubMed ID: 30700475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose escalation to 84 Gy with concurrent chemotherapy in stage III NSCLC appears excessively toxic: Results from a prematurely terminated randomized phase II trial.
    Hallqvist A; Bergström S; Björkestrand H; Svärd AM; Ekman S; Lundin E; Holmberg E; Johansson M; Friesland S; Nyman J
    Lung Cancer; 2018 Aug; 122():180-186. PubMed ID: 30032828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-Dimensional Radiation Therapy to the Primary Tumor With Concurrent Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study From PPRA-RTOG, China.
    Su S; Li T; Lu B; Wang X; Li J; Chen M; Lu Y; Bai Y; Hu Y; Ouyang W; Ma Z; Li Q; Li H; Wang Y
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):769-77. PubMed ID: 26530745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protocol for the isotoxic intensity modulated radiotherapy (IMRT) in stage III non-small cell lung cancer (NSCLC): a feasibility study.
    Haslett K; Franks K; Hanna GG; Harden S; Hatton M; Harrow S; McDonald F; Ashcroft L; Falk S; Groom N; Harris C; McCloskey P; Whitehurst P; Bayman N; Faivre-Finn C
    BMJ Open; 2016 Apr; 6(4):e010457. PubMed ID: 27084277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study.
    Jeter MD; Gomez D; Nguyen QN; Komaki R; Zhang X; Zhu X; O'Reilly M; Fossella FV; Xu T; Wei X; Wang H; Yang W; Tsao A; Mohan R; Liao Z
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):730-737. PubMed ID: 29248169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between intensity modulated radiotherapy and survival in patients with stage III non-small cell lung cancer treated with chemoradiotherapy.
    Koshy M; Malik R; Spiotto M; Mahmood U; Rusthoven CG; Sher DJ
    Lung Cancer; 2017 Jun; 108():222-227. PubMed ID: 28625640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is intermediate radiation dose escalation with concurrent chemotherapy for stage III non-small-cell lung cancer beneficial? A multi-institutional propensity score matched analysis.
    Rodrigues G; Oberije C; Senan S; Tsujino K; Wiersma T; Moreno-Jimenez M; Kim TH; Marks LB; Rengan R; De Petris L; Ramella S; DeRuyck K; De Dios NR; Warner A; Bradley JD; Palma DA
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):133-9. PubMed ID: 25835622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individualised isotoxic accelerated radiotherapy and chemotherapy are associated with improved long-term survival of patients with stage III NSCLC: a prospective population-based study.
    De Ruysscher D; van Baardwijk A; Steevens J; Botterweck A; Bosmans G; Reymen B; Wanders R; Borger J; Dingemans AM; Bootsma G; Pitz C; Lunde R; Geraedts W; Oellers M; Dekker A; Lambin P
    Radiother Oncol; 2012 Feb; 102(2):228-33. PubMed ID: 22100659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of concurrent high-dose three-dimensional conformal radiotherapy with chemotherapy using cisplatin and vinorelbine for unresectable stage III non-small-cell lung cancer.
    Sekine I; Sumi M; Ito Y; Horinouchi H; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Kubota K; Tamura T
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):953-9. PubMed ID: 21377282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin.
    Uyterlinde W; Belderbos J; Baas C; van Werkhoven E; Knegjens J; Baas P; Smit A; Rikers C; van den Heuvel M
    Clin Lung Cancer; 2013 Sep; 14(5):541-8. PubMed ID: 23835165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base.
    Sher DJ; Koshy M; Liptay MJ; Fidler MJ
    Cancer; 2014 Jul; 120(13):2060-8. PubMed ID: 24692108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent chemoradiotherapy with tomotherapy in locally advanced Non-Small Cell Lung Cancer: a phase I, docetaxel dose-escalation study, with hypofractionated radiation regimen.
    Bearz A; Minatel E; Rumeileh IA; Borsatti E; Talamini R; Franchin G; Gobitti C; Del Conte A; Trovò M; Baresic T
    BMC Cancer; 2013 Oct; 13():513. PubMed ID: 24176164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.